Sanofi (SNY) to Release Earnings on Thursday

Key Points

• Sanofi will report Q1 2026 results before the market opens on Thursday, April 23, with analysts expecting earnings of $0.9330 per share and revenue of $10.8086 billion; the earnings call is scheduled for 7:00 AM ET.
• Sanofi raised its annual dividend to $2.4225, with an ex-dividend/record date of May 4 and a payment date of June 3.
• Shares trade around $48 with a market cap of $117.12 billion and a P/E of 13.34; analysts' consensus is a Hold with a $58.00 price target (one Strong Buy, four Buy, eight Hold).

Sanofi (NASDAQ:SNY - Get Free Report) is anticipated to post its Q1 2026 results before the market opens on Thursday, April 23rd. Analysts expect Sanofi to post earnings of $0.9330 per share and revenue of $10.8086 billion for the quarter. Individuals may review the information on the company's upcoming Q1 2026 earning report for the latest details on the call scheduled for Thursday, April 23, 2026 at 7:00 AM ET.

Sanofi Stock Performance

Shares of SNY opened at $48.02 on Thursday. The company has a market capitalization of $117.12 billion, a PE ratio of 13.34, a price-to-earnings-growth ratio of 1.19 and a beta of 0.42. Sanofi has a one year low of $43.32 and a one year high of $55.73. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.09 and a quick ratio of 0.73. The company's fifty day moving average price is $46.46 and its 200 day moving average price is $48.04.

Sanofi Increases Dividend

The company also recently announced an annual dividend, which will be paid on Wednesday, June 3rd. Investors of record on Monday, May 4th will be issued a $2.4225 dividend. This is a boost from Sanofi's previous annual dividend of $2.04. The ex-dividend date is Monday, May 4th. This represents a yield of 502.0%. Sanofi's payout ratio is 44.44%.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Deutsche Bank Aktiengesellschaft reiterated a "buy" rating on shares of Sanofi in a report on Friday, January 16th. Wall Street Zen cut Sanofi from a "strong-buy" rating to a "buy" rating in a research report on Saturday, February 21st. TD Cowen reissued a "hold" rating on shares of Sanofi in a research report on Tuesday, December 30th. Bank of America cut Sanofi from a "buy" rating to a "neutral" rating in a research report on Thursday, February 12th. Finally, Weiss Ratings upgraded shares of Sanofi from a "sell (d+)" rating to a "hold (c-)" rating in a report on Thursday, April 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Hold" and a consensus price target of $58.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Measured Wealth Private Client Group LLC bought a new position in shares of Sanofi during the 3rd quarter worth about $29,000. Palisade Asset Management LLC bought a new position in shares of Sanofi during the 3rd quarter worth about $30,000. Sittner & Nelson LLC bought a new position in shares of Sanofi during the 3rd quarter worth about $47,000. WealthCollab LLC increased its holdings in shares of Sanofi by 21.6% during the 3rd quarter. WealthCollab LLC now owns 1,538 shares of the company's stock worth $73,000 after purchasing an additional 273 shares during the period. Finally, Brown Brothers Harriman & Co. increased its holdings in shares of Sanofi by 618.7% during the 3rd quarter. Brown Brothers Harriman & Co. now owns 2,271 shares of the company's stock worth $107,000 after purchasing an additional 1,955 shares during the period. Institutional investors own 14.03% of the company's stock.

Sanofi Company Profile

Sanofi NASDAQ: SNY is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.